Plasma Chromogranin A as Marker for Survival in Patients With Metastatic Endocrine Gastroenteropancreatic Tumors

Clinical Gastroenterology and Hepatology

Volumn 6, Issue 7, 2008, Pages 820-827

  Arnold, Rudolf ^a   Wilke, Alexandra ^a   Rinke, Anja ^a   Mayer, Christina ^a   Kann, Peter Herbert ^a   Klose, Klaus Jochen ^a   Scherag, André ^a,b   Hahmann, Maik ^a   Müller, Hans Helge ^a   Barth, Peter ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOGRANIN A;

ADULT; AGED; ARTICLE; BRONCHUS TUMOR; CANCER GROWTH; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DUODENUM TUMOR; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS TUMOR; PROGNOSIS; STOMACH TUMOR; SURVIVAL TIME; TUMOR VOLUME;

ADULT; AGED; CHROMOGRANIN A; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; PROGNOSIS; STATISTICS AS TOPIC; SURVIVAL; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 45849150025     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2008.02.052     Document Type: Article

References (26)

1. Arnold R., Simon B., and Wied M. Treatment of neuroendocrine GEP tumours with somatostatin analogues. Digestion 62 Suppl 1 (2000) 84-91
2. Godwin J.D. Carcinoid tumors: an analysis of 2837 cases. Cancer 36 (1975) 560-569
3. Williams E.D., and Sandler M. The classification of carcinoid tumors. Lancet 75 (1963) 140-146
4. Modlin I.M., Lye K.D., and Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 97 (2003) 934-959
5. Rindi G., Azzoni C., La Rosa S., et al. ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: prognostic evaluation by pathological analysis. Gastroenterology 116 (1999) 532-542
6. Arnold R., Rinke A., Klose K.-J., et al. Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. Clin Gastroenterol Hepatol 3 (2005) 761-771
7. Hsiao R.J., Seeger R.C., Yu A.L., et al. Chromogranin A in children with neuroblastoma. Serum concentration parallels diease stage and predicts survival. J Clin Invest 85 (1990) 1555-1559
8. Nobels F.R., Kwekkeboom D.J., Coopmans W., et al. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Metab 82 (1997) 2622-2628
9. Norheim I., Theodorsson-Norheim E., Brodin E., et al. Tachykinins in carcinoid tumours: their use as a tumor marker and possible role in the carcinoid flush. J Clin Endocrinol Metab 63 (1986) 605-612
10. Turner G.B., Johnston B.T., McCance D.R., et al. Circulating markers of prognosis and response to treatment in patients with midgut carcinoid tumours. Gut 55 (2006) 1586-1591
11. Prinz R.A., Bermes E.W., Kimmel J.R., et al. Serum markers for pancreatic islet cell and intestinal carcinoid tumors: a comparison of neuron specific enolase, β-human chorionic gonadotropin and pancreatic polypeptide. Surgery 94 (1983) 1019-1023
12. Groβmann M., Trautmann M.E., Poertl S., et al. Alpha-subunit and human chorionic gonadotropin-β immunoreactivity in patients with malignant endocrine gastro-entero-pancreatic tumors. Eur J Clin Invest 24 (1994) 131-136
13. Taupenot L., Harper K.L., and O′Connor D.T. The chromogranin-secretogranin family. N Engl J Med 348 (2003) 1134-1149
14. O′Connor D.T., and Frigon R.P. Chromogranin A, the major catecholamine storage vesicle soluble protein: multiple size forms, subcellular storage, and regional distribution in chromaffin and nervous tissue elucidated by radioimmunoassay. J Biol Chem 259 (1984) 3237-3247
15. Öberg K., Tiensuu Janson E., and Erikson B. Tumor markers in neuroendocrine tumours. Ital J Gastroenterol hepatol 3 Suppl 2 (1993) S160-S162
16. Goebel S.U., Serrano J., Yu F., et al. Prospective study of the value of serum chromogranin A or serum gastrin levels in the assessment of the presence, extent, or growth of gastrinomas. Cancer 85 (1999) 1470-1483
17. Janson E.T., Holmberg L., Stridsberg M., et al. Carcinoid tumors: analysis of prognostic factors and survival in 301 patients. Ann Oncol 8 (1997) 685-690
18. Öberg K., Tiensuu Janson E., and Erikkson B. Tumour markers in neuroendocrine tumours. Ital J Gastroenterol Hepatol 3 (1999) S160-S162
19. Stivanello M., Berruti A., Torta M., et al. Circulating chromogranin A in the assessment of patients with neuroendocrine tumours: a single institution experience. Ann Oncol 12 Suppl 2 (2001) S73-S77
20. Nikou G.C., Lygidakis N.J., Toubanakis C., et al. Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin A, somatostatin receptor scintigraphy and somatostatin analogues. Hepatogastroenterology 52 (2005) 731-741
21. Kölby L., Bernhardt P., Sward C., et al. Chromogranin A as a determinant of midgut carcinoid tumour volume. Regul Pept 120 (2004) 269-273
22. Ardill J.E.S., and Erikkson B. The importance of the measurement of circulating markers in patients with neuroendocrine tumours of the pancreas and gut. Endocr Relat Cancer 1 (2003) 459-462
23. Stridsberg M., Erikkson B., Öberg K., et al. A comparison between three commercial kits for chromogranin A measurements. J Endocrinol 177 (2003) 337-341
24. Woltering E.A., Hilton R.S., Zolfoghary C.M., et al. Validation of serum versus plasma measurements of chromogranin A levels in patients with carcinoid tumors: lack of correlation between absolute chromogranin A levels and symptom frequency. Pancreas 33 (2006) 250-254
25. Gluer C.C., Barkmann R., Hahn H.K., et al. Parametric biomedical imaging: what defines the quality of quantitative radiological approaches?. RoFo 178 (2006) 1187-1201
26. Bashir S., Gibril F., Ojeaburu J.V., et al. Prospective study of the ability of histamine, serotonin or serum chromogranin A levels to identify gastric carcinoids in patient with gastrinomas. Aliment Pharmacol Ther 16 (2002) 1367-1382